A new window into the natural history of human papillomavirus infection: A view from the ALTS (Atypical Squamous Cells of Undetermined Signilicance/Low- Grade Squamous Intraepithelial Lesions Triage Study) trial

Journal of Infectious Diseases

Volumn 195, Issue 11, 2007, Pages 1560-1562

  Franco, Eduardo L ^a   Trottier, Helen ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PREVENTION; CANCER RISK; DISEASE DURATION; HUMAN; MOLECULAR EPIDEMIOLOGY; NOTE; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; SQUAMOUS EPITHELIUM; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS DETECTION; WART VIRUS;

BAYES THEOREM; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MARKOV CHAINS; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 34249076015     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516791     Document Type: Note

References (23)

1. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical cancer screening. N Engl J Med 2003; 348:489-90.
2. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337:76-84.
3. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Glissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204.
4. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.
5. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072-9.
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
7. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88:63-73.
8. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
9. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-40.
10. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8.
11. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
12. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-74.
13. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184:1508-17.
14. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002; 186:462-9.
15. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158:486-94.
16. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190:2077-87.
17. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24(Suppl 1):S1-15.
18. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. ALTS Study Group. J Natl Cancer Inst 2001; 93:293-9.
19. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; American Society for Colposcopy and Cervical Pathology-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120-9.
20. Wright TC Jr, Cox JT, Massad LS, Carlson J, Twiggs LB, Wilkinson EJ; American Society for Colposcopy and Cervical Pathology. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2003; 189:295-304.
21. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, for the ASCUS/ LSIL Triage Study (ALTS) Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions. J Infect Dis 2007; 195:1582-9 (in this issue).
22. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
23. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-8.